Scheibye-Knudsen Lab
Featured Project

Scheibye-Knudsen Lab

Ageing
Mental Health
Respiratory Disease
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Licensing OutreachView on Molecule
Investment
$ 250,000
Initiated
23.6.2021
Approval
88% Voted Yes
Project Details
Morten Scheibye-Knudsen
Research Lead
AT A GLANCE
Stage
Early Stage Preclinical Discovery
Area
Drug Repurposing
Status
Ongoing
Patent
Not Filed Yet

Background

The study, consisting of over 1.4 billion prescriptions, found that a number of prescription drugs were highly associated with longer life- and health-span in long-live populations. Here, we present a unique investment opportunity. We seek to validate these observations through a series of carefully conducted wet lab experiments. If successful, this work could result in the repurposing of several FDA-approved therapeutics for the purpose of extending human lifespan, at a lower cost and over faster timelines than conceivably possible with de novo drug discovery. This unique investment opportunity allows savvy longevity investors the chance to own a share of the potential intellectual property generated from these studies, and in turn, a potential share in the future of life extension.

Aims, Hypothesis & Results

The global elderly population is projected to substantially increase throughout the 21st century. By the year 2100 a fifth of the total world population will be aged 65 or older posing a serious socioeconomic challenge to societies world-wide. Interventions that ensure healthy aging are therefore of critical importance.

Timeline

Pre-Clinical Studies 1: Testing in Fruit Flies and Human Cells
Required Funding: $500,000
Status: Ongoing
Duration: 24 Months

Testing the identified drugs ability to attenuate features of aging in a controlled laboratory setting. Here, we will test the molecules in human cells and in the animal model drosophila melanogaster (fruit flies). We are testing the drugs in human cells to rapidly understand how the molecules affect human cellular aging. Fruit flies are used extensively in biomedical research and particular aging research as they have a short lifespan of about 60 days.

VitaDAO Board Evaluation Writeup

This program focuses on testing and developing three of these small molecules as possible interventions in aging. Specifically, we will test the drugs on human cell cultures and in various animal models. Importantly, the current anti-aging market stands at 200 billion USD, even without a single scientifically proven treatment. Our molecules targets this specific market with the aim of letting everyone live healthier, happier and longer lives.

Latest Project Updates
17
August
2021
17
August
2021
5. Morten IP-NFT Transfer Ceremony with Molecule

The vote has passed, the decision is made: Morten Scheibye-Knudsen Lab will be the first research organisation to fund their longevity research via an IPNFT. This historic moment needs to be celebrated properly!

29
July
2021
29
July
2021
4. AMA Scheibye-Knudsen Lab Funding Proposal
15
June
2021
15
June
2021
3. Morten-Cell-Lab
23
April
2021
23
April
2021
2. Lab-Tour with Research Lead Morten

Lab-Tour with Founder Morten

Take a quick look at Scheibye-Knudsen Lab in Copenhagen, where the first longevity research project to be funded by VitaDAO is prepared.

19
April
2021
19
April
2021
1. The Flies are ready!

The Flies are ready! Scheibye-Knudsen Lab Update

4
April
2021
4
April
2021
0. Intro to The Scheibye-Knudsen Lab

A first intro by the team of The Scheibye-Knudsen Lab, one of the first research project getting funded by VitaDAO.

23
June
2021
Project Initiated!

Discover more projects & initiatives

Discovery of novel mitophagy activators for Alzheimer’s disease
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
Korolchuk Lab
Korolchuck lab proposes a drug discovery programme with the aim of identifying novel bioactive autophagy inducers. Activation of autophagy is considered a promising therapeutic approach to combat ageing and age-related diseases.

About VitaDAO

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?